Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodality Protocol for Locally Advanced NSCLC
NCT00043108Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2002
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Primary endpoints: Toxic Death Rate at 5 years and Complete Resection Rate at 5 years. Started Jul 2002; status: completed.
02
Drugs
paclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00043108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043108.